We used a second in vivo fibrosis disease model (myocardial infarction [MI] model, see Methods) and tested the potential protective effect of the WWP2-N/FL LOF on cardiac fibrosis and function post-MI. The gene discussed is WWP2; the disease is myocardial infarction.